A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 2
Completed
- Conditions
- Multiple Myeloma
- Registration Number
- NCT00096837
- Lead Sponsor
- Pharmacyclics LLC.
- Brief Summary
The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
- Relapsed or Refractory Multiple Myeloma
- ≥ 18 years old
- Able to provide consent for participation
- ECOG status 0-2
Lab values:
- ANC ≥ 1,000/µL
- WBC count ≥ 2.0/µL
- Hemoglobin ≥ 8.0 g/dL
- Platelet count ≥ 50,000/µL
- AST and ALT ≤ 2 x ULN
- Total Bilirubin ≤ 2 x ULN
- Creatinine ≤ 2.0 mg/dL
and
- Not pregnant or lactating
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Rate of complete response, partial response and stable disease (clinical benefit rate)
- Secondary Outcome Measures
Name Time Method Progression-free survival Safety and tolerability
Trial Locations
- Locations (1)
Robert H. Lurie Comprehensive Cancer Center
🇺🇸Chicago, Illinois, United States